SYNAGIS® (palivizumab) PRIOR AUTHORIZATION REQUEST

PRESCRIBER FAX FORM

ONLY the provider may complete this form. This form is for prospective, concurrent, and retrospective reviews.

Incomplete forms will be returned for additional information. The following documentation is required for preauthorization consideration. For formulary information and to download additional forms, please visit www.bcchpil.com PATIENT AND INSURANCE INFORMATION Today's Date: Patient Name (First): DOB (mm/dd/yyyy): City, State, Zip: Patient Telephone: Patient Address: BCBS ID Number: Group Number: PRESCRIBER/CLINIC INFORMATION Prescriber Name: Prescriber NPI#: Specialty: Contact Name: Clinic Name: Clinic Address: City, State, Zip: Phone #: Secure Fax #: PLEASE ATTACH ANY ADDITIONAL INFORMATION THAT SHOULD BE CONSIDERED WITH THIS REQUEST Patient's Diagnosis - ICD code plus description: Medication Requested: Strength: *Your request will be reviewed for the generic equivalent unless you specify brand is required. Dosing Schedule: Quantity per Month: Patient's Height: ____cm GESTATIONAL AGE AT BIRTH: _____ weeks ____ days Patient's Weight: kg □ No If yes, when was treatment with the requested medication started?_____ □ No _____ and date(s) given:_____ If yes, provide number of doses received: If no, provide date first dose will be given: ____ Please provide the patient's current RSV season: □ No Is the requested agent being prescribed for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus? ☐ No □ No □ No \square No Has the patient required medical support for CLD in the 6 months prior to the ☐ No If yes, please explain:_ ☐ No If yes, please explain: Does the patient have congenital abnormalities of the airway or a neuromuscular condition impairing ☐ No □ No □ No 12. Is the patient an infant with lesions adequately corrected by surgery but continues to require medication for congestive heart failure? □ No Please continue on page 2.

6037 ILMC SYNA 1020 Page 1 of 2

Patie	nt Name (First):	Last:		M:	DOB (mm/dd/yy):
13. Does the patient have acyanotic heart disease, is receiving medication to control congestive heart					
	failure, and will require cardiac sur	rgical procedures	?		Yes
14.	Does the patient have moderate-to-se	vere pulmonary h	ypertension?		Yes
15.	i. Does the patient have mild cardiomyopathy AND is currently receiving medical therapy				
	for the condition?				Yes
16.	Does the patient have cyanotic heart of	lisease?			Yes No
	If yes, is the prescriber a pediatric	cardiologist or ha	s consulted with a pediatric	c cardio	logist? Yes No
17.	Does the patient have cystic fibrosis? .				Yes No
	If yes, does the patient have any of the following? Check all that apply.				
	☐ Chronic lung disease				
	☐ Manifestations of severe lung disease				
	Please explain:				
	☐ Nutritional compromise				
	☐ Weight for length <10 th percentile				
18.	18. Please list all reasons for selecting the requested medication , dosing schedule , and quantity over alternatives (e.g., contraindications, allergies or history of adverse drug reactions to alternatives, lower dose tried)				
19.	Please list all other medications the patient is currently taking for treatment of this diagnosis.				
20.	20. Please list all medications the patient has previously tried and failed for treatment of this diagnosis. (Please specify if the patient has tried brand-name products, generic products, or over-the-counter products.)				
	Date(s): Date(s):				Date(s):
	[Date(s):			Date(s):
	[Date(s):			Date(s):
Please fax or mail this form to: Blue Cross and Blue Shield of Illinois c/o Prime Therapeutics LLC, Clinical Review Department 2900 Ames Crossing Road Eagan, Minnesota 55121 TOLL FREE Fax: 877.243.6930 Phone: 800.285.9426			CONFIDENTIALITY NOTICE: This communication is intended only for the use of the individual entity to which it is addressed and may contain information that is privileged or confidential. If the reader of this message is not the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please notify the sender immediately by telephone at 866.202.3474 and return the original message to Blue Cross and Blue Shield of Illinois c/o Prime Therapeutics via U.S. Mail. Thank you for your cooperation.		

6037 ILMC SYNA 1020 Page **2** of **2**